Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Takeda Pharmaceutical Co. Ltd.. (1/5/18). "Press Release: Takeda Announces Intention to Acquire TiGenix. Expands Takeda’s Late Stage Pipeline and Leadership in Gastroenterology". Osaka.

Organisations Organisation Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
  Organisation 2 TiGenix N.V. (Euronext + Nasdaq: TIG)
  Group Takeda (Group)
Products Product darvadstrocel (Cx601)
  Product 2 investment banking
Index term Index term TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share ANNOUNCED
Persons Person Plump, Andrew (Takeda 201610 CMO + CSO)
  Person 2 Bravo, Eduardo (Nordic Nanovector 201807– CEO before TiGenix + Cellerix + Sanofi-Aventis + SKB)

Record changed: 2018-01-08


Picture [iito] – Putting Information into Context 600x102px

More documents for Takeda (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px

» top